Pionyr Immunotherapeutics
Biotechnology ResearchUnited States51-200 Employees
In 2015, Pionyr Immunotherapeutics embarked on a journey to forge a new path in immuno-oncology for patients in need. We are a clinical stage company discovering and developing novel antibody therapeutics that dramatically alter the tumor microenvironment (TME) and enhance the body’s immune defense against cancer – with the potential to eliminate it. Pionyr's Myeloid Tuning™ cutting-edge technology is based on the discovery that “tuning” the tumor microenvironment to favor immune-activating cells and disable immune-suppressing cells improves the body’s ability to combat cancer, particularly in combination with checkpoint inhibitors. Additionally, Pionyr is building a pipeline of transmembrane and intracellular targets using our cutting-edge technologies and translational assays. Immuno-oncology is a complex field, which is why Pionyr has recruited a bold and growing team with extensive experience in immunology, immuno-oncology, target discovery, and immunotherapy development. Our “Pionyrs” are banded together by innovation, integrity, team empowerment, respect and one unified voice to translate meaningful science into promising opportunities for treating cancer.
1-888-653-2347 
support@leadiq.com 
